RELAFEN DS 1,000 MG TABLET

What it is

RELAFEN DS 1,000 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as nabumetone, under the trade name “RELAFEN DS”.

FDA gives its dosage form as tablet and its route as oral.

The labeler, the company named on the label, is Carwin Pharmaceutical Associates, LLC.

FDA’s Established Pharmacologic Class for it is Nonsteroidal Anti-inflammatory Drug.

The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes).

NADAC classes it in its brand rate-setting class B-ANDA, and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $950.00 for 30 tablets (30 × $31.66667 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-06-17. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 4, carried forward from the previous file; 6, the CMS Covered Outpatient Drug Product File S/I/N drug category was not applied when grouping drugs for the calculation.

The NADAC of all 2 NDCs was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: those prices took effect on 2026-06-17. The file is new; the price is not.

What NADAC measures · Why 30 tablets · NADAC explanation codes · Carried-forward prices

All 2 NDCs

• 15370-0170-30 · Carwin Pharmaceutical Associates, LLC · $31.66667 per EA · eff. 2026-06-17 filed carried forward
• 15370-0170-60 · Carwin Pharmaceutical Associates, LLC · $31.66667 per EA · eff. 2026-06-17 filed carried forward

Other strengths, forms and brands

2 other products in the NADAC file share the FDA nonproprietary name nabumetone with RELAFEN DS 1,000 MG TABLET.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-06-17, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 2 NDCs’ NADAC prices is $31.66667 per EA filed.

Of the 154 other products in FDA’s Nonsteroidal Anti-inflammatory Drug class priced per EA, 1 has a higher middle NADAC price and 153 a lower one. The one in the middle is INDOMETHACIN 25 MG CAPSULE, at $0.09341 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-06-17, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part D paid $1,566.72 for 30 tablets, at an average of $52.22414 per EA in 2024 (2024-01-01 to 2024-12-31) for “Relafen Ds” and “Nabumetone”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 610 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
• If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.